Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Mitsubishi Tanabe Pharma America Announces Nearly 4,000 ALS Patients in the U.S. Have Been Treated with RADICAVA ORS® (edaravone) | |||||||||
By: PR Newswire Association LLC. - 26 Jan 2023 | Back to overview list |
||||||||
JERSEY CITY, N.J., Jan. 26, 2023 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that nearly 4,000 people with amyotrophic lateral sclerosis (ALS) have received RADICAVA ORS® (edaravone) since the therapy became available in the U.S. in June 2022, and 79% of patients who started treatment with RADICAVA ORS or intravenous (IV) RADICAVA® (edaravone) between June 1, 2022 and September 30, 2022 have continued treatment for three months or more through December.1,2 To date, more than 600 U.S. healthcare providers (HCPs) have prescribed RADICAVA ORS since the treatment became available.3 Additionally, nearly 2,000 U.S. HCPs have prescribed RADICAVA ORS and/or RADICAVA to one or more of their patients.4 "We are pleased to see the number of new patients beginning treatment with RADICAVA ORS continue to increase over time, and the strong adherence rates among patients," said Atsushi Fujimoto, President, MTPA. "The needs of patients with ALS remain at the forefront of our efforts at MTPA, and this is underscored by the data insights we continue to gather and real-life experiences from the ALS community." RADICAVA ORS is an oral formulation of edaravone that offers the same efficacy as RADICAVA and was shown in a pivotal trial to help slow the loss of physical function in ALS.5,6 To learn more about RADICAVA ORS, including information about dosing and administration, visit RADICAVA.com. "When I received my diagnosis five years ago, I was anxious about the potential impact this disease would have on my day-to-day plans," said Kate Nycz, a retired nurse practitioner and advocate living with ALS. "RADICAVA ORS fits into my daily routine, and offers me the flexibility to take my treatment by mouth, instead of through an IV, while I'm at home or when I'm on the go doing the things that I love, like mentoring others with ALS and traveling around the world with my husband." The initial treatment cycle starts with daily dosing of RADICAVA ORS for 14 days followed by a 14-day drug-free period. Subsequent treatment cycles include daily dosing 10 out of 14 days followed by a 14-day drug-free period. People taking RADICAVA ORS should use the provided five milliliter syringe that comes with the product and should not use a household teaspoon to measure the medication. RADICAVA ORS should be stored upright at room temperature between 68°F-77°F and protected from light.5 In clinical trials, the most common adverse reactions (?10%) reported in RADICAVA-treated patients were contusion (15%), gait disturbance (13%), and headache (10%). In an open-label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS. RADICAVA and RADICAVA ORS are contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients.5 See Important Safety Information below. About RADICAVA® (edaravone) and RADICAVA ORS® (edaravone) Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and Mitsubishi Tanabe Pharma Development America, Inc. (MTDA), commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc. (MTPA). The MTPC group companies began researching ALS in 2001 through an iterative clinical platform over a 13-year period. In 2015, edaravone was approved as RADICUT® for the treatment of ALS in Japan and South Korea. Marketing authorizations were subsequently granted in Canada (October 2018), Switzerland (January 2019), Indonesia (July 2020), Thailand (April 2021) and Malaysia (December 2021). Marketing authorization for RADICAVA® Oral Suspension was granted in Canada in November 2022, and RADICUT® Oral Suspension 2.1% was granted regulatory approval in Japan in December 2022. To date, in the U.S., RADICAVA and RADICAVA ORS have been used to treat over 9,000 patients, with over 1.2 million days of therapy, and have been prescribed by nearly 2,000 HCPs.1,4,7 IMPORTANT SAFETY INFORMATION Hypersensitivity Reactions Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA or RADICAVA ORS, treat per standard of care, and monitor until the condition resolves. Sulfite Allergic Reactions Adverse Reactions Pregnancy To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. INDICATION For more information, including full Prescribing Information, please visit www.RADICAVA.com. About Mitsubishi Tanabe Pharma America, Inc. About Mitsubishi Tanabe Pharma Development America, Inc. About Mitsubishi Tanabe Pharma Corporation Media inquiries:
View original content to download multimedia:https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-announces-nearly-4-000-als-patients-in-the-us-have-been-treated-with-radicava-ors-edaravone-301731026.html SOURCE Mitsubishi Tanabe Pharma America, Inc. |
|||||||||
|
|||||||||
Copyright 2023 PR Newswire Association LLC. | Back to overview list |